沙库巴曲缬沙坦钠治疗中老年慢性心力衰竭患者的临床疗效及其对心功能的影响

Clinical effect of sabatrix valsartan sodium in the treatment of middle and old patients with chronic heart failure and the impact on cardiac function

目的探讨沙库巴曲缬沙坦钠治疗中老年慢性心力衰竭(以下简称心衰)患者的临床疗效及其对心功能的影响。方法选取2019年10月—2021年10月平度巿人民医院收治的80例中老年慢性心衰患者作为研究对象,采用随机数字表法分为对照组40例和研究组40例。对照组仅采用常规治疗,研究组在对照组基础上采用沙库巴缬沙坦钠治疗,2组均持续治疗14 d。比较2组治疗前及治疗后14 d临床指标[心率(HR)、血氧饱和度(SaO_(2))、平均动脉压(MAP)]、心功能指标[左心室射血分数(LVEF)、B型脑钠肽(BNP)水平及6 min步行试验(6MWT)]、血清学指标[血肌酐(SCr)、C反应蛋白(CRP)及心肌肌钙蛋白T(cTnT)],并观察2组不良反应发生情况。结果治疗后14 d,2组HR、SaO_(2)、MAP高于治疗前,且研究组高于对照组(P<0.01)。治疗后14 d,2组LVEF高于治疗前,BNP水平低于治疗前,6MWT长于治疗前,且研究组LVEF高于对照组,BNP水平低于对照组,6MWT长于对照组(P<0.05)。治疗后14 d,2组SCr、CRP、c Tn T水平低于治疗前,且研究组低于对照组(P<0.05)。研究组不良反应总发生率为2.50%,与对照组的10.00%比较,差异无统计学意义(χ^(2)=0.853,P=0.356)。结论沙库巴曲缬沙坦钠治疗中老年慢性心衰患者的效果较好,可有效稳定患者生命体征,改善心功能,提高运动耐量,减轻心肌损伤,且安全性较高。

Objective To discuss the clinical effect of sabatrix valsartan sodium in the treatment of middle and old patients with chronic heart failure and the impact on cardiac function.Methods A total of 80 cases of middle and old patients with chronic heart failure were selected from October 2019 to October 2021 in Pingdu People’s Hospital as research objects,and they were divided into control group(n=40)and study group(n=40)according to random number table method.Patients in control group were given conventional therapy,and patients in study group were given sabatrix valsartan sodium based on control group,both groups were treated with 14 days.Clinical indexes(HR,SaO_(2),MAP),cardiac function indexes(LVEF,BNP,6MWT),serological index(SCr,CRP,c Tn T)before treatment and at 14 days after treatment,incidence of adverse reactions were compared between the two groups.Results At 14 days after treatment,HR,SaO_(2),MAP in the two groups were higher than those before treatment,and the study group were higher than those in control group(P<0.01).At14 days after treatment,LVEF in the two groups was higher than that before treatment,BNP level was lower than that before treatment,6MWT was longer than that before treatment,and the LVEF in study group was higher than that in control group,BNP level was lower than that in control group,6MWT was longer than that in control group(P<0.05).At 14 days after treatment,levels of SCr,CRP,c Tn T were lower than those before treatment,and the study group were lower those in control group(P<0.05).There was no significant difference of the incidence of adverse reactions between study group(2.50%)and control group(10.00%)(χ^(2)=0.853,P=0.356).Conclusion Sabatrix valsartan sodium has better clinical effect in the treatment of middle and old patients with chronic heart failure,which can effectively stabilize patients’vital signs,improve cardiac function,increase exercise tolerance,and reduce myocardial injury,with high safety.